SOPHiA Genetics SA(SOPH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.15 | Insider Own | 27.42% | Shs Outstand | 85.1M | Perf Week | 13.05% |
| Market Cap | 0.68B | Forward P/E | - | EPS next Y | 33.26% | Insider Trans | -2.57% | Shs Float | 61.8M | Perf Month | -4.89% |
| Enterprise Value | 0.63B | PEG | - | EPS next Q | -0.2 | Inst Own | 43.71% | Short Float | 1.62% | Perf Quarter | 40.56% |
| Income | -0.08B | P/S | 7.87 | EPS this Y | 19.83% | Inst Trans | 21.59% | Short Ratio | 1.68 | Perf Half Y | 52.68% |
| Sales | 0.09B | P/B | 8.16 | EPS next 5Y | 32.33% | ROA | -43.02% | Short Interest | 1.00M | Perf YTD | 70.66% |
| Book/sh | 0.98 | P/C | 6.3 | EPS past 3/5Y | 5% -13.68% | ROE | -101.22% | 52W High | -11.25% ($8.98) | Perf Year | 75.55% |
| Cash/sh | 1.26 | P/FCF | - | Sales past 3/5Y | 17.56% 22.16% | ROIC | -56.87% | 52W Low | 108.09% ($3.83) | Perf 3Y | 119.56% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -4.8% | Gross Margin | 66.63% | Volatility(W/M) | 4.82% 6.84% | Perf 5Y | -43.83% |
| Dividend TTM | - | EV/Sales | 7.34 | Sales Y/Y TTM | 23.65% | Oper. Margin | -84.33% | ATR (14) | 0.45 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.55 | EPS Q/Q | 9.04% | Profit Margin | -93.86% | RSI (14) | 57.38 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.69 | Sales Q/Q | 27.22% | SMA20 | 8.46% ($7.35) | Beta | 1.08 | Target Price | $9.75 |
| Payout | - | Debt/Eq | 0.74 | Earnings | 2026/11/3 | SMA50 | 1.05% ($7.89) | Rel Volume | 0.35 | Prev Close | $7.87 |
| Employees | 415 | LT Debt/Eq | 0.71 | EPS/Sales Surpr. | -42.86% 7.32% | SMA200 | 34.23% ($5.94) | Avg Volume(3M) | 0.59M | Price | $7.97 |
| IPO | 2021/7/23 | Option/Short | Yes/Yes | Trades | 2260 | Volume | 208,073 | Change | 1.27% |
🧬 This is a global healthcare information services company that interprets genomic data through its cloud-based AI analytics platform. Its SOPHiA DDM Platform helps more than 750 medical and research institutions worldwide standardize and analyze genomic data, leveraging data network effects in the field of precision medicine as its core competitive strength.
Over the past 1 year, on the higher side
11% below its 1-year high.
Traded less than usual. That is 35% of its average volume.
Next earnings report: November 3
4 days to go.
SOPH has a sound balance sheet but weak earning power
Of every $100 in sales, $84.33 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $787. Peers typically go for $181.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -43.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 43.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
MEDI Harbor Health Care ETF <0.01% 
ONEQ Fidelity Nasdaq Composite Index ETF <0.01% It ranks #18 of 41 in the industry
Based on market cap of $678M.
PHR#17 Phreesia Inc $778M PER 74.2 SOPH#18 SOPHiA Genetics SA $678M PER - 
WEAV#19 Weave Communications Inc $595M PER - 
NRC#20 NRC Health $520M PER 84.5 
EVH#21 Evolent Health Inc $481M PER - 
FAQ
What kind of company is SOPH?
SOPH belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of SOPH?
The market cap of SOPH is approximately $678M, ranking 2,910 within its sector.
What is the 52-week high and low for SOPH?
SOPH has recorded a 52-week high of $8.98 and a low of $3.83.
